Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hangzhou Diagens Biotechnology Co PS Ratio?
Hangzhou Diagens Biotechnology CoHKSE:02526 -3.48%8 PS Ratio is 390.69 as of Aug. 14, 2026, which is 17% above its 10-year median of 335.28. GuruFocus rates HKSE:02526 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Hangzhou Diagens Biotechnology Co ranks worse than 98.88% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Hangzhou Diagens Biotechnology Co's share price is HK$361.00.
Hangzhou Diagens Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$0.92. Hence, Hangzhou Diagens Biotechnology Co's PS Ratio for today is 390.69.
Warning Sign:
Hangzhou Diagens Biotechnology Co Ltd stock PS Ratio (=570.11) is close to 1-year high of 570.11.
HKSE:02526'
s PS Ratio Range Over the Past 10 Years
Min: 253.25 Med: 335.28 Max: 495.67
Current: 390.69
During the past 3 years, Hangzhou Diagens Biotechnology Co's highest PS Ratio was 495.67. The lowest was 253.25. And the median was 335.28.
HKSE:02526's PS Ratio is ranked worse than 98.88% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 3.01
vs HKSE:02526: 390.69
Hangzhou Diagens Biotechnology Co (HKSE:02526) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Hangzhou Diagens Biotechnology Co PS Ratio Related Terms
Hangzhou Diagens Biotechnology Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Diagens Biotechnology Co PS Ratio Chart
Hangzhou Diagens Biotechnology Co Annual Data
Trend
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
0.00
Hangzhou Diagens Biotechnology Co Quarterly Data
Dec23
Dec24
Sep25
Dec25
Jun26
PS Ratio
0.00
0.00
0.00
0.00
0.00
HKSE:02526 vs ABT, SYK, MDT: PS Ratio Comparison
For the Medical Devices subindustry, Hangzhou Diagens Biotechnology Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Diagens Biotechnology Co PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Diagens Biotechnology Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Hangzhou Diagens Biotechnology Co's PS Ratio falls into.
Hangzhou Diagens Biotechnology Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Hangzhou Diagens Biotechnology Co's Share Price of today is HK$361.00. Hangzhou Diagens Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.92.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a PS Ratio of 390.69 as of Aug. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Hangzhou Diagens Biotechnology Co and its competitors. This is 17% above median its historical median of 335.28. Over the past decade, Hangzhou Diagens Biotechnology Co's PS Ratio has ranged from 253.25 to 495.67. According to the industry distribution chart, Hangzhou Diagens Biotechnology Co ranks #794 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 98.9%.
Is Hangzhou Diagens Biotechnology Co's PS Ratio too high?
Hangzhou Diagens Biotechnology Co's current PS Ratio of 390.69 is 17% above median its 10-year median of 335.28. Over the past 10 years, this metric has ranged from a low of 253.25 to a high of 495.67. The Medical Devices & Instruments industry median PS Ratio is 3.01. Hangzhou Diagens Biotechnology Co's value of 390.69 is 12879.7% above this industry median. Based on the distribution chart, Hangzhou Diagens Biotechnology Co ranks #794 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Hangzhou Diagens Biotechnology Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Diagens Biotechnology Co's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Diagens Biotechnology Co ranks #794 out of 803 companies for PS Ratio. This places Hangzhou Diagens Biotechnology Co in the lower half of its industry. The industry median PS Ratio is 3.01. Hangzhou Diagens Biotechnology Co's value of 390.69 is 12879.7% above this benchmark. Historically, Hangzhou Diagens Biotechnology Co's own PS Ratio has ranged from 253.25 to 495.67 over the past decade. While the company's 10-year median is 335.28 vs. the industry median of 3.01, Hangzhou Diagens Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 3.01, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Diagens Biotechnology Co's current PS Ratio of 390.69 is 12879.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Hangzhou Diagens Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 3.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Diagens Biotechnology Co's current PS Ratio is 390.69, which is 17% above median its own 10-year median of 335.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Diagens Biotechnology Co stock overvalued right now?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a current PS Ratio of 390.69. The current PS Ratio is 390.69, which is 17% above median its 10-year median of 335.28 and 12879.7% above the Medical Devices & Instruments industry median of 3.01. Hangzhou Diagens Biotechnology Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Hangzhou Diagens Biotechnology Co (HKSE:02526), the current PS Ratio is 390.69 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
8GF Score
Get the complete analysis for HKSE:02526
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02526 has been successfully added to your 
